Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 250


Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.

Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, Munshi N, Singhal S, Mehta J, Tindle S, Nelson J, Bracy D, Mattox S, Tricot G.

J Clin Oncol. 1998 Apr;16(4):1547-53.


The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients.

Lefrère F, Zohar S, Ghez D, Delarue R, Audat F, Suarez F, Hermine O, Damaj G, Maillard N, Ribeil JA, Azagury M, Misbahi R, Jondeau K, Cavazzana-Calvo M, Dal Cortivo L, Varet B.

Bone Marrow Transplant. 2006 Apr;37(8):725-9.


Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.

Somlo G, Sniecinski I, Odom-Maryon T, Nowicki B, Chow W, Hamasaki V, Leong L, Margolin K, Morgan R Jr, Raschko J, Shibata S, Tetef M, Molina A, Berenson RJ, Forman SJ, Doroshow JH.

Blood. 1997 Mar 1;89(5):1521-8.


Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone.

Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A, Toor A, Zangari M, Badros A, Morris C, Vesole DH, Siegel D, Jagannath S, Barlogie B.

Br J Haematol. 2001 Jan;112(1):242-7.


Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.

Alegre A, Tomás JF, Martínez-Chamorro C, Gil-Fernández JJ, Fernández-Villalta MJ, Arranz R, Díaz MA, Granda A, Bernardo MR, Escudero A, López-Lorenzo JL, Fernández-Rañada JM.

Bone Marrow Transplant. 1997 Aug;20(3):211-7.


Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.

Sosman JA, Stiff P, Moss SM, Sorokin P, Martone B, Bayer R, van Besien K, Devine S, Stock W, Peace D, Chen Y, Long C, Gustin D, Viana M, Hoffman R.

J Clin Oncol. 2001 Feb 1;19(3):634-44.


Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.

Koç ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L, Fox RM, Szekely EM, Tainer N, Lazarus HM.

J Clin Oncol. 2000 May;18(9):1824-30.


Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients.

Nowrousian MR, Waschke S, Bojko P, Welt A, Schuett P, Ebeling P, Flasshove M, Moritz T, Schuette J, Seeber S.

Ann Oncol. 2003;14 Suppl 1:i29-36.


Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.

Watanabe H, Watanabe T, Suzuya H, Wakata Y, Kaneko M, Onishi T, Okamoto Y, Abe T, Kawano Y, Kagami S, Takaue Y.

Bone Marrow Transplant. 2006 Apr;37(7):661-8.


Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF.

Demirer T, Ayli M, Ozcan M, Gunel N, Haznedar R, Dagli M, Fen T, Genc Y, Dincer S, Arslan O, Gürman G, Demirer S, Ozet G, Uysal A, Konuk N, Ilhan O, Koc H, Akan H.

Br J Haematol. 2002 Feb;116(2):468-74.


Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma.

Lefrere F, Makke J, Fermand J, Marolleau J, Dal Cortivo L, Alberti C, Mouton V, Benbunan M, Miclea J.

Bone Marrow Transplant. 1999 Sep;24(5):463-6.


Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.

Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Färber L, Burger KJ, Goldschmidt H, Hoelzer D, Haas R.

Bone Marrow Transplant. 1998 Oct;22(7):625-30.


Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients.

Kröger N, Zeller W, Fehse N, Hassan HT, Krüger W, Gutensohn K, Lölliger C, Zander AR.

Br J Haematol. 1998 Sep;102(4):1101-6.


Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.

Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B.

Blood. 1995 Jan 15;85(2):588-96. Review.


Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma.

Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, Fassas A, Tindle S, Nelson J, Juttner C, Tsukamoto A, Hallagan J, Atkinson K, Reading C, Hoffman R, Barlogie B.

Blood. 1998 Jun 15;91(12):4489-95.


Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization.

Watts MJ, Sullivan AM, Leverett D, Peniket AJ, Perry AR, Williams CD, Devereux S, Goldstone AH, Linch DC.

J Clin Oncol. 1998 Apr;16(4):1554-60.


GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.

Zumberg MS, Leather HL, Nejame C, Meyer C, Wingard JR.

Cytotherapy. 2002;4(6):531-8.

Items per page

Supplemental Content

Write to the Help Desk